cabergoline teva 0.5 mg tabl.
teva pharma belgium sa-nv - cabergoline 0,5 mg - tablet - 0,5 mg - cabergoline 0.5 mg - cabergoline
apo-cabergoline
apotex nz ltd - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose magnesium stearate - indicated for the inhibition of physiological lactation soon after delivery. (1) after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. (2) after still birth or abortion.
cabergoline teva 0.5mg tablets
teva pharma b.v. (mijdrecht) industrieweg 23, p.o. box 217, 3640 ae mijdrecht, netherlands - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals
cabergoline tablet
mylan pharmaceuticals inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg
cabergoline tablet
apotex corp. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg
cabergoline tablet
avera mckennan hospital - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg
cabergoline tablet
ingenus pharmaceuticals, llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )
cabergoline tablet
remedyrepack inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )
cabergoline tablet
sola pharmaceuticals, llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).
cabergoline tablet
cobalt pharmaceuticals company - cabergoline - tablet - 0.5mg - cabergoline 0.5mg - ergot-derivative dopamine receptor agonists